Related Experiment Video
Updated: Jan 2, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas
Carmen Salvador-Coloma1,2, María Saigí3, Roberto Díaz-Beveridge1
1Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Background:
Primary cardiac tumors are extremely rare; most are myxomas with a benign prognosis. However, primary sarcomas are highly aggressive and treatment options are limited. Radical surgery is often not feasible and conventional therapies provide only modest results. Due to the rare nature of primary cardiac tumors, there are no proper randomized studies to guide treatment. Their complexity requires alternative approaches in order to improve treatment efficacy.
Methods:
We isolated DNA from 5 primary cardiac sarcomas; the quality of DNA from 3 of them was sufficient to perform high-resolution single nucleotide polymorphism (SNP) array analysis.
Results:
In the present study, molecular karyotyping revealed numerous segmental chromosomal alterations and amplifications affecting actionable genes that may be involved in disease initiation and/or progression. These include chromosomal break flanking AKT2 in undifferentiated pleomorphic rhabdomyosarcoma, chromosomal break in promoter of TERT, and gain of CDK4 and amplification of MDM2 in inflammatory myofibroblastic tumor. We detected segmental break flanking MOS in high-grade myxofibrosarcoma. In addition, the high number of chromosomal aberrations in high-grade myxofibrosarcoma may cause multiple tumor-specific epitopes, supporting the study of immunotherapy treatment in this type of aggressive tumor.
Conclusion:
Our results provide a genetic rationale that supports an alternative, personalized therapeutic management of primary cardiac sarcomas.
Insights
Primary cardiac sarcomas are aggressive tumors with limited treatment options. Genetic analysis revealed actionable targets, supporting personalized therapies for these rare cancers.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Primary cardiac tumors are rare, with sarcomas being highly aggressive and challenging to treat.
- Limited randomized studies exist for primary cardiac tumors, necessitating alternative treatment strategies.
- Conventional therapies offer modest efficacy for primary cardiac sarcomas.
Purpose of the Study:
- To investigate the genetic landscape of primary cardiac sarcomas.
- To identify actionable molecular targets for personalized therapeutic management.
Main Methods:
- DNA was isolated from five primary cardiac sarcoma samples.
- High-resolution single nucleotide polymorphism (SNP) array analysis was performed on three samples.
Main Results:
- Molecular karyotyping identified numerous segmental chromosomal alterations and gene amplifications.
- Specific alterations include chromosomal breaks flanking AKT2, TERT promoter, MOS, and gains/amplifications of CDK4 and MDM2.
- High-grade myxofibrosarcoma exhibited numerous chromosomal aberrations, suggesting potential for immunotherapy.
Conclusions:
- Genetic findings provide a rationale for personalized therapeutic approaches in primary cardiac sarcomas.
- Identification of actionable genes supports targeted therapy development.
- Potential for immunotherapy in high-grade myxofibrosarcoma warrants further investigation.
